HJHaang Jeung-Maarse

Haang Jeung-Maarse

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Haang Jeung-Maarse has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Open Science in Undergraduate Medical Education: An International Framework for Transparency, Responsibility, and Professional Identity Formation

    by Haang Jeung-Maarse, Rosa L. Ecos, Luisa F. Jimenez-Soto, Philipp Linde, Mara Müssigmann, Sandra Schuh, Sarah Wahlster, Changryul Claud Yi

    Concerns about reproducibility, transparency, and research waste have intensified debates about trust in medical research and health-related sciences. Although Open science initiatives aim to address these challenges, their role in undergraduate medical education remains underexplored. Undergraduate medical education typically emphasizes appraisal of published evidence but pays less attention to how research is conducted, governed, and disseminated. This article proposes an international conceptual framework that positions Open science as part of professional formation in undergraduate medical education. The framework comprises three domains: epistemic transparency, ethical responsibility, and professional identity formation. Together, they describe how learners engage with knowledge production, uncertainty, and responsibility. Rather than prescribing curricular models, the framework offers adaptable principles that can be mapped onto existing structures such as competency-based programs in diverse contexts. By framing Open science as a formative orientation rather than a technical skill set, it links medical education to professional responsibility and the public role of medicine.

  • Open Access

    Oxytocin effects on amygdala reactivity to angry faces in males and females with antisocial personality disorder

    by Haang Jeung-Maarse, Mike M. Schmitgen, Ruth Schmitt, Katja Bertsch, Sabine C. Herpertz

    The amygdala is a key region in current neurocircuitry models of reactive aggression as it is crucially involved in detecting social threat and provocation. An increased amygdala reactivity to angry faces has been reported in aggression-prone individuals and the neuropeptide oxytocin (OT) could dampen anger-related amygdala reactivity in a number of mental disorders. One example is the antisocial personality disorder (ASPD) which has so far only been studied in limited numbers. To address the question whether OT can normalize amygdala hyperreactivity to emotional faces, we conducted a functional magnetic resonance imaging experiment with 20 men and 18 women with ASPD and 20 male and 20 female healthy control (HC) participants in a double-blind, randomized, placebo (PLC)-controlled within-subject design. Participants were exposed to an emotion classification task (fearful, angry, and happy faces) after receiving an intranasal dose (24 IU) of synthetic OT or PLC. We found OT to attenuate right amygdala hyperactivity to angry faces in participants with ASPD to such an extent that the intensity of amygdala activity in the ASPD group in the OT condition decreased to the level of amygdala activity in the PLC condition in the HC group. There was also a trend that OT effects were generally larger in women than in men. These findings suggest that OT differentially modulates the amygdala following social threatening or provoking cues in dependence of psychopathology (ASPD vs. HC) and sex (male vs. female). Particularly female ASPD patients could benefit from OT in the treatment of reactive aggression.


  • Neues zur Diagnostik und Therapie von Persönlichkeitsstörungen – Änderungen in ICD‑11

    by Haang Jeung-Maarse, Sabine C. Herpertz

    Zusammenfassung Persönlichkeitsstörungen (PS) treten häufig auf und zeigen hohe Remissionsraten im Langzeitverlauf, wobei psychosoziale Genesung bei einem beträchtlichen Teil ausbleibt. Im ICD-11 wird die traditionelle Auffassung, eine PS sei von hoher Stabilität, verlassen. Stattdessen beträgt die Mindestdauer zwei Jahre. Im diagnostischen Prozess werden drei Schweregrade (leicht, mäßig, schwer) sowie fünf sog. prominente Persönlichkeitsmerkmale differenziert. Optional kann zusätzlich ein Borderline-Qualifizierungsmerkmal kodifiziert werden. Hinreichende empirische Evidenz liegt alleine für die Behandlung der Borderline-PS (BPS) vor. Hier haben sich störungsspezifische Psychotherapien, insbesondere die dialektisch-behaviorale Therapie (DBT) und mentalisierungsbasierte Therapie (MBT) als besonders wirksam erwiesen. Therapiemodule, die sich auf Funktionsbeeinträchtigungen und prominente Persönlichkeitsmerkmale beziehen, könnten die bestehende Lücke in der störungsspezifischen Behandlung von PS schließen.